Psychopharmacology

Effective psychiatric training empowers residents to take ownership of patient care, fostering confidence and critical thinking through real-world decision-making.

Combining cognitive behavioral therapy with medication enhances ADHD treatment in adults, showing significant benefits within 3 months.

Simplistic explanations and convenient scapegoats belie the complexity of mass shootings.

It is time to redefine treatment resistance, a definition in which we emphasize comprehensive evaluations and personalized approaches for better patient outcomes.

Psychiatrists confront the challenge of treatment-resistant depression, balancing honesty and compassion while redefining realistic recovery goals for patients.

Cognition Therapeutics advances zervimesine phase 2 trial, exploring its potential to slow cognitive decline in Alzheimer disease patients.

Exploring the prevalence and implications of psychotropic polypharmacy in patients taking clozapine with treatment-resistant schizophrenia.

The FDA has approved the Leqembi subcutaneous autoinjector for at-home Alzheimer disease treatment.

Read the full, exclusive transcript from the inaugural "Brain Trust: Conversations in Clinical Psychopharmacology" video with Joseph F. Goldberg, MD, and Marlene Freeman, MD.

New research highlights lithium's crucial role in brain health, revealing its potential to combat Alzheimer disease and enhance mental wellness.

FDA approves Tonmya, a groundbreaking fibromyalgia treatment, offering hope for pain relief after 15 years without new options.

Antidepressant treatment for late-life depression enhances cognitive functions like memory and learning, linking symptom relief to cognitive improvement.

Researchers uncover how serotonin receptor 5-HT1A influences drug interactions, paving the way for faster, targeted psychiatric treatments.

Explore the evolution and therapeutic potential of GLP-1, a key incretin in diabetes management and weight loss solutions.

Stay updated on key psychopharmacology developments, including new treatments for schizophrenia and breakthroughs in depression therapy.

Serum drug levels provide crucial insights for optimizing psychiatric treatment, enhancing patient outcomes in cases of schizophrenia and OCD.

Benzodiazepines spark ongoing debate, balancing effective anxiety relief with addiction risks, as cultural attitudes shape their use and perception.

Research reveals significant risks of neonatal complications linked to in utero valproic acid exposure, emphasizing the need for careful management during pregnancy.

Valproic acid poses significant risks during pregnancy, including congenital malformations and neurodevelopmental disorders, necessitating careful treatment planning.

New analysis qualifies OPTIMUM study, finding antidepressant combinations more effective than switching for treatment resistant depression in elderly.

In this CME article, discover effective strategies for prescribing MAOIs in treating major depressive disorder.

Learn more about how serum drug levels enhance psychiatric treatment by providing critical insights into medication efficacy and patient outcomes.

How can we teach psychopharmacology in a way that engages today's digital-native psychiatry residents and enhances real-world application?

GLP-1 receptor agonists emerge as potential game-changers in psychiatric treatment, targeting mental disorders and improving cognitive function.

Roger S. McIntyre, MD, FRCPC, shares the backstory and pharmacology of incretins to better understand the role of GLP-1 RAs in psychiatry.

Learn more about how to best assess and treat tardive dyskinesia.

Now more than ever, capturing and scaling the ingredients that make for compelling and impactful teaching for trainees is vital to our future.

The RECOVER open label trial demonstrated positive results for brilaroxazine for schizophrenia.

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.

In this CME article, learn more about the essential role of MAOIs in treating resistant depression and anxiety.